29.01

7.76% 2.09

After Hours: 29.01

Capricor Therapeutics Inc (CAPR)

Overview News Price History Option Chain Financials Why CAPR Down? Discussions Forecast Stock Split

Capricor Therapeutics Inc stock is traded at $29.01, with a volume of 1.12M. It is up +7.76% in the last 24 hours and down -15.20% over the past month. Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Previous Close:

$26.92

Open:

$27.52

24h Volume:

1.12M

Relative Volume:

0.87

Market Cap:

$1.68B

Revenue:

$11.13M

Net Income/Loss:

$-105.04M

P/E Ratio:

-12.86

EPS:

-2.2565

Net Cash Flow:

$-81.54M

1W Performance:

-4.35%

1M Performance:

-15.20%

6M Performance:

+409.84%

1Y Performance:

+163.49%

1-Day Range:

$27.09

$29.12

1-Week Range:

$26.60

$30.93

52-Week Range:

$4.30

$40.37

Capricor Therapeutics Inc Stock (CAPR) Company Profile

Name

Capricor Therapeutics Inc

Sector

Healthcare (1099)

Industry

Biotechnology (615)

Phone

(310) 358-3200

Address

10865 ROAD TO THE CURE, SAN DIEGO, CA

Employee

231

Twitter

@Capricor

Next Earnings Date

2026-05-12

Latest SEC Filings

CAPR's Discussions on Twitter

Compare CAPR vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CAPR Capricor Therapeutics Inc	29.01	1.62B	11.13M	-105.04M	-81.54M	-2.2565
VRTX Vertex Pharmaceuticals Inc	430.44	110.81B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	649.76	66.02B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	804.25	48.27B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.48	38.22B	4.29B	577.22M	641.34M	4.2086
ONC Beone Medicines Ltd Adr	308.74	30.41B	5.76B	514.49M	1.10B	4.4813

Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-30-25	Initiated	Alliance Global Partners	Buy
Jun-26-25	Initiated	B. Riley Securities	Buy
May-20-25	Initiated	Roth Capital	Buy
Oct-21-24	Initiated	Piper Sandler	Overweight
May-17-24	Initiated	Oppenheimer	Outperform
Jan-05-24	Initiated	Cantor Fitzgerald	Overweight
Oct-26-22	Initiated	Ladenburg Thalmann	Buy
Dec-26-18	Downgrade	Maxim Group	Buy → Hold
Jan-26-18	Reiterated	H.C. Wainwright	Buy
Sep-15-17	Reiterated	H.C. Wainwright	Buy
Feb-13-17	Resumed	Rodman & Renshaw	Buy
Jul-06-16	Resumed	H.C. Wainwright	Buy
Jun-15-16	Initiated	ROTH Capital	Buy

View All

Capricor Therapeutics Inc Stock (CAPR) Latest News

May 20, 2026

Should you sell your Capricor Therapeutics stock? - Cantech Letter

May 20, 2026

Capricor’s Earnings Call: Deramiocel Drives High-Stakes Pivot - TipRanks

May 20, 2026

May 19, 2026

CAPR stock sinks after-hours: Capricor launches legal fight over DMD therapy rollout ahead of FDA review - MSN

May 19, 2026

CAPRICOR (CAPR) CFO exercises stock options to acquire 3,000 shares - Stock Titan

May 19, 2026

Capricor Therapeutics Stock Jumps After-Hours As Retail Cheers Fresh FDA Attempt After Duchenne Therapy Rejection - MSN

May 17, 2026

Top 10 healthcare stocks by forward P/E: From Capricor's 418x to Alignment Healthcare's 48x - MSN

May 17, 2026

May 15, 2026

Roth MKM Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $38 - Moomoo

May 15, 2026

CAPR Stock Price, Quote & Chart | CAPRICOR THERAPEUTICS INC (NASDAQ:CAPR) - ChartMill

May 15, 2026

Capricor Faces Revenue Risk as Dependence on Nippon Shinyaku Puts Deramiocel Commercialization in Jeopardy - TipRanks

May 15, 2026

May 14, 2026

Capricor Therapeutics, Inc. Q1 2026 earnings preview - MSN

May 14, 2026

Capricor (CAPR) Q1 2026 Earnings Transcript - AOL.com

May 14, 2026

Capricor Therapeutics (CAPR) director boosts stake via 3,937-share option exercise - Stock Titan

May 14, 2026

CAPR: Capricor Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits

May 14, 2026

May 13, 2026

CAPRICOR THERAPEUTICS, INC. 1Q 2026: Revenue $9.4M, EPS ($0.59) — 10-Q Summary - TradingView

May 13, 2026

[10-Q] CAPRICOR THERAPEUTICS, INC. Quarterly Earnings Report - Stock Titan

May 13, 2026

CAPR Reiterated by HC Wainwright & Co. -- Price Target Maintained at $60 - GuruFocus

May 13, 2026

Capricor drops following filing of lawsuit against Nippon Shinyaku - MSN

May 13, 2026

Capricor stock price target held at $63 by B.Riley on FDA progress - Investing.com UK

May 13, 2026

H.C. Wainwright Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $60 - Moomoo

May 13, 2026

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q1 2026 Earnings Call Transcript - Insider Monkey

May 13, 2026

Capricor Lawsuit Puts Duchenne Therapy Launch Plans And Valuation In Focus - Yahoo Finance

May 13, 2026